Form SC 13G/A NLS Pharmaceutics Ltd. Filed by: Lind Global Fund II LP
NLS Pharmaceutics Ltd. - Common Shares (NLSP)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
NLSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NLSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NLSP alerts
High impacting NLS Pharmaceutics Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
NLSP
News
- NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger AgreementAccesswire
- NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing RequirementsAccesswire
- NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin DependenceAccesswire
- NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing RulesAccesswire
- NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share SplitAccesswire
NLSP
Sec Filings
- 11/15/24 - Form 6-K
- 11/14/24 - Form SC
- 11/12/24 - Form 6-K
- NLSP's page on the SEC website